Perioperative Immunotherapy Moves Deeper Into Resectable NSCLC
A phase 2 trial in resectable non-small cell lung cancer is set to test whether extending neoadjuvant treatment can improve tumor eradication before surgery. The study will compare two perioperative schedules built around a PD-1 inhibitor, ipilimumab, and platinum-based chemotherapy in 90 treatment-naïve patients with clinical stage IIB, IIIA, or IIIB disease limited to resectable N2 involvement.
The design is straightforward but clinically ambitious. One cohort will receive two cycles of the PD-1 antibody plus chemotherapy and one cycle of ipilimumab. The other will receive four cycles of the PD-1 antibody plus chemotherapy and two cycles of ipilimumab. Both arms use the same checkpoint backbone, but the exposure window is longer in the second cohort, creating a direct test of whether more prolonged immune priming translates into a higher pathological complete response rate.
Why the Trial Focuses on pCR Before Surgery
The primary endpoint is pathological complete response, a clinically meaningful measure in the neoadjuvant setting because it captures how deeply treatment has cleared viable tumor from the resected specimen. In resectable NSCLC, pCR has become one of the clearest early signals that a regimen may be doing more than shrinking a mass on imaging; it may be changing the biology of the tumor before the surgeon ever enters the chest.
That distinction matters in a disease where microscopic residual disease can drive relapse after apparently complete resection. Immunotherapy offers a biologic rationale for preoperative use: intact tumor tissue can serve as an antigen reservoir, allowing PD-1 blockade and CTLA-4 inhibition to expand T-cell activity while chemotherapy may increase antigen release and alter the tumor microenvironment. The perioperative window is therefore not just a scheduling exercise. It is an attempt to push the immune system into a more durable antitumor state before surgery removes the primary lesion.
Two Exposure Schedules, One Curative-Intent Pathway
The multicenter study assigns patients in a 1:1 ratio to Cohort A or Cohort B. In Cohort A, participants receive two cycles of PD-1 inhibitor plus chemotherapy and one cycle of ipilimumab. In Cohort B, participants receive four cycles of PD-1 inhibitor plus chemotherapy and two cycles of ipilimumab. The PD-1 agent is administered intravenously at 200 mg every three weeks, while ipilimumab is given at 1 mg/kg every six weeks.
Chemotherapy is tailored to histology. Patients with non-squamous NSCLC receive pemetrexed plus carboplatin or cisplatin. Patients with squamous NSCLC receive nab-paclitaxel plus carboplatin or cisplatin. This split reflects the long-standing histologic divide in lung cancer treatment, where pemetrexed performs best in non-squamous tumors and taxane-platinum combinations remain central in squamous disease.
The trial also builds in a curative-intent surgical sequence. Eligible patients will undergo surgery 22 to 42 days after the final neoadjuvant dose, followed by investigator-selected adjuvant therapy beginning 29 to 42 days after surgery. Postoperative follow-up will continue for up to five years, creating a window to track recurrence patterns after the perioperative strategy has been completed.
Patient Selection Is Tight by Design
The eligibility criteria reflect the risks of combining dual checkpoint inhibition with chemotherapy before lung resection. Participants must be adults with cytologically or histologically confirmed NSCLC, ECOG performance status 0 or 1, measurable disease by RECIST 1.1, and adequate organ and marrow function. Pulmonary reserve must also support the planned operation, with forced expiratory volume in one second and maximal voluntary ventilation each at least 50% of predicted value.
Molecular selection is equally important. Patients with non-squamous tumors must have testing that confirms the absence of sensitizing EGFR mutations and ALK rearrangements. Squamous tumors do not require the same testing, although anyone with known EGFR or ALK alterations is excluded. The study also requires enough tissue for PD-L1 testing during screening, signaling an interest in biomarker-driven interpretation even though the primary endpoint remains pathological response.
The exclusion list is long, and for good reason. Small cell carcinoma, neuroendocrine carcinoma, sarcoma, lymphoepithelioma-like carcinoma, salivary gland tumors, and mesenchymal components are ruled out. So are tumors invading critical mediastinal structures, superior sulcus tumors, contralateral pulmonary nodules, and suspected or confirmed brain metastases. Prior exposure to PD-1, PD-L1, PD-L2, CTLA-4, or other checkpoint-targeting therapies is prohibited, as is recent use of investigational agents, immune-modulating traditional medicines, or live attenuated vaccines.
Safety Will Matter as Much as Response
The regimen’s promise rests on a familiar immunotherapy tradeoff: stronger antitumor activity may come with more immune-related toxicity, more treatment delays, or more surgical complexity. In the perioperative setting, those risks are especially consequential because a patient must remain fit enough to reach the operating room on schedule. The protocol therefore embeds careful laboratory thresholds for blood counts, liver function, renal function, and coagulation, along with pregnancy precautions and long-term contraception requirements for patients at risk of conception.
A shorter neoadjuvant course may reduce the chance of toxicity before surgery, but it may also leave less time for immune activation. A longer course may deepen response while raising the likelihood of adverse events or operating-room delays. The trial is built around that tension. The comparison between the two cohorts will not only ask whether more treatment is better, but whether more treatment is still compatible with timely curative resection.
What This Study Could Clarify for Surgeons and Oncologists
Because the study is still not recruiting, no outcome data are available yet. The real value lies in the structure of the question. By pairing PD-1 blockade with ipilimumab and chemotherapy in a randomized perioperative framework, the investigators are trying to define how much immune exposure is enough before surgery in resectable NSCLC.
If the longer schedule improves pCR without compromising operability, it could support a more intensive neoadjuvant strategy in selected patients with stage II to III disease. If the added cycles fail to improve response or create avoidable toxicity, the shorter course may remain the more practical path. Either result will be informative because the trial is asking a question that matters at the bedside: how to balance immune intensity, surgical timing, and curative intent in a population that is still potentially operable.